June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
The efficacy of aflibercept in the treatment of neovascular age-related macular degeneration previously treated with bevacizumab or ranibizumab
Author Affiliations & Notes
  • Laura Hall
    Ophthalmology and Visual Science, Yale University School of Medicine, New Haven, CT
  • Nazlee Zebardast
    Ophthalmology and Visual Science, Yale University School of Medicine, New Haven, CT
  • Ron Adelman
    Ophthalmology and Visual Science, Yale University School of Medicine, New Haven, CT
  • Footnotes
    Commercial Relationships Laura Hall, None; Nazlee Zebardast, None; Ron Adelman, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 3799. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Laura Hall, Nazlee Zebardast, Ron Adelman; The efficacy of aflibercept in the treatment of neovascular age-related macular degeneration previously treated with bevacizumab or ranibizumab. Invest. Ophthalmol. Vis. Sci. 2013;54(15):3799.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To study the visual outcomes and change in central macular thickness (CMT) in patients with neovascular age-related macular degeneration (AMD) previously treated with ranibizumab and/or bevacizumab who were subsequently switched to aflibercept (VEGF Trap-Eye, Eylea®). Aflibercept was approved based on randomized clinical trial data which studied patients with untreated AMD. This study aims to determine the utility of aflibercept in patients who received previous anti-VEGF treatment.

Methods: A retrospective chart review of 22 patients who met the inclusion criteria: 1) previous anti-VEGF treatment for AMD, 2) at least 6-month follow-up and 3) available medical record. The main outcome measures were best-corrected Snellen visual acuity (BCVA) logMAR and central macular thickness (CMT) as measured by optical coherence tomography (OCT). These values were recorded at the initial baseline visit prior to the first aflibercept injection and at subsequent 1-month, 3-month, and 6-month follow-up clinic visits and/or injections.

Results: The study population included 4 men and 18 women aged 78.0±3.20 years (mean±SEM) who received 5.36±0.38 aflibercept injections. Thirteen patients previously received only bevacizumab (9.00±2.26 injections), one received only ranibizumab (11 injections) and 8 received both anti-VEGF agents (mean 21.4 injections). BCVA logMAR at the initial baseline visit was 0.50±0.07 (mean±SEM) (mean VA 20/64), 1-month 0.52±0.07 (20/66), 3-month 0.41±0.07 (20/52), and 6-month 0.43±0.10 (20/54) (p-value 0.14, two-tailed paired t-test comparing initial and 6-month follow-up). CMT results for initial baseline visit were 301±30.8µm, 1 month 238±13.5, 3-month 236±11.1, and 6-month 247±10.7 (p-value 0.07, two-tailed paired t-test comparing initial and 6-month follow-up).

Conclusions: These findings demonstrate a trend towards improvement from baseline to 6-month follow-up in both BCVA and CMT in AMD patients previously treated with the mainstay agents ranibizumab and/or bevacizumab who were switched to aflibercept. Given the small sample size a larger study will be beneficial.

Keywords: 412 age-related macular degeneration • 688 retina • 466 clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×